BETHESDA, Md.—New research has shown that a unique pattern of microRNAs, small RNA molecules that regulate gene activity, can accurately predict whether liver cancer will spread and whether liver cancer patients will have shorter or longer survival, even patients with early stage disease.

 

The study, which appeared online Jan. 7 in Hepatology, was conducted by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and colleagues at Ohio State University, and the Liver Cancer Institute in Shanghai, China.

 

"The aggressive nature of hepatocellular carcinoma, a prevalent type of liver cancer, is largely due to its tendency to spread or recur after surgery," said the study's lead author, Anuradha Budhu, a staff scientist in the laboratory of Xin Wei Wang, head of the Liver Carcinogenesis Section of NCI's Center for Cancer Research (CCR). "Identifying new diagnostic and prognostic biomarkers for liver cancer is a first step in alleviating the dismal outcome of this disease."

 

miRNAs, have been implicated in various aspects of human disease, including cancer. Their abundance in different tissues and cancer types indicate that miRNAs are functionally significant and have the potential to be used as cancer biomarkers. Since miRNAs can effectively regulate the activity of multiple cancer-related genes and pathways, they are prime candidates for coordinating the intricate events that lead to the spread of cancer, which is known as metastasis.

 

In the study, researchers analyzed the miRNA expression profiles in cancerous and noncancerous liver samples from 131 patients with or without metastasis who underwent surgery at the Liver Cancer Institute and Zhongshan Hospital in Shanghai. The analysis revealed a set of 20 miRNAs with different patterns of expression in tumors with metastasis compared to tumors without metastasis. miRNAs are capable of regulating the expression of one or more genes, including cancer-related genes, potentially affecting multiple cell functions that could lead to malignancy.

 

Using the new gene expression profile, the researchers found that patients with the metastasis-miRNA profile had a two-fold higher risk of shorter survival compared to those without the profile. This latest finding in hepatocellular carcinoma, or HCC, in combination with earlier research by this team on early stage HCC and the tumor microenvironment, suggests potential for increasing the accuracy of liver cancer diagnosis and prognosis, as well as in monitoring recurrence.